In Vivo |
Mcl-1 inhibitor 3 (oral administration; 3, 10, or 30 mg/kg; 6 hours) causes a significant loss of luminescence (∼40%) over vehicle at 30 mg/kg,This effect was observed with unbound drug levels in plasma, the [plasma]u/OPM-2 IC50 values are 0.24, 0.93 and 3.65 μM in 3, 10, 30 mg/kg doses,respectively[1]. Mcl-1 inhibitor 3 (oral administration; 10, 30, or 60 mg/kg; 6 hours) activates Bak by 8-fold at 30 mg/kg and by 14-fold at 60 mg/kg in this OPM-2 Luc assay,this test is based on the detection of activated Bak in nude mice subcutaneously injected with via electrochemiluminescence.[1]. Mcl-1 inhibitor 3 (oral administration; 10, 30, or 60 mg/kg; 30 days) led to a robust dose-dependent tumor growth inhibition at 30 mg/kg (44% TGI) and 34% tumor regression when the animals were dosed at 60 mg/kg.Lastly, no body weight loss is observed in any of the mice in this study efficacy models[1]. Animal Model: Nude miceinjected with HEK293 cells[1] Dosage: 3, 10, or 30 mg/kg Administration: Oral administration Result: Showed a disruption of the Mcl-1/Bak interaction in this in vivo model. Animal Model: Nude mice injected with human OPM-2 multiple myeloma tumor cells[1] Dosage: 10, 30, or 60 mg/kg Administration: Oral administration Result: Exhibited a inhibition of tumor growth without any toxicity.
|